银屑病回顾性药物基因组学研究:KLK7在TNF信号中的作用
发现rs1991820与抗TNF生物制剂应答相关(P=1.30×10^-6),rs62264137与甲氨蝶呤应答相关(P=2.94×10^-6),且KLK7表达在银屑病表皮中升高并影响抗TNF应答。
要点
- rs1991820与抗TNF生物制剂治疗应答相关(P=1.30×10^-6)。
- rs62264137与甲氨蝶呤应答相关(P=2.94×10^-6),并关联KLK7和CD200的皮肤mRNA表达。
- 抑制KLK7表达可降低角质形成细胞对TNF的促炎反应。
核心结论
- 研究提示细胞因子应答的遗传调控可预测临床药物应答,并支持药物基因组位点与抗TNF应答之间的关联,如KLK7所示。
研究设计与样本
- 回顾性药物基因组研究,纳入1942例已基因分型的银屑病患者,采用自我评估的治疗应答。
- 整合表观基因组学、转录组学和纵向临床队列数据,对与药物应答关联最强的信号提供生物学解释。
主要发现
- rs1991820与抗TNF生物制剂治疗应答相关(P=1.30×10^-6)。
- rs62264137与甲氨蝶呤应答相关(P=2.94×10^-6),该标记也与KLK7(P=1.0×10^-12)和CD200(P=5.4×10^-6)的皮肤mRNA表达水平相关。
- 免疫组化和单细胞RNA测序显示KLK7表达在银屑病表皮中升高,并突出其对抗TNF治疗的应答性。
- 抑制KLK7表达后,角质形成细胞对TNF的促炎反应降低。
临床怎么用
- 研究提示遗传标记可能用于预测银屑病患者对特定治疗方案的应答,支持药物基因组学在治疗选择中的潜在应用。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple treatment options are available for the management of psoriasis, but clinical response varies among individual patients and no biomarkers are available to facilitate treatment selection for improved patient outcomes. OBJECTIVES: To utilize retrospective data to conduct a pharmacogenetic study to explore the potential genetic pathways associated with drug response in the treatment of psoriasis. METHODS: We conducted a retrospective pharmacogenetic study using self-evaluated treatment response from 1942 genotyped patients with psoriasis. We examined 6 502 658 genetic markers to model their associations with response to six treatment options using linear regression, adjusting for cohort variables and demographic features. We further utilized an integrative approach incorporating epigenomics, transcriptomics and a longitudinal clinical cohort to provide biological implications for the topmost signals associated with drug response. RESULTS: Two novel markers were revealed to be associated with treatment response: rs1991820 (P = 1.30 × 10-6) for anti-tumour necrosis factor (TNF) biologics; and rs62264137 (P = 2.94 × 10-6) for methotrexate, which was also associated with cutaneous mRNA expression levels of two known psoriasis-related genes KLK7 (P = 1.0 × 10-12) and CD200 (P = 5.4 × 10-6). We demonstrated that KLK7 expression was increased in the psoriatic epidermis, as shown by immunohistochemistry, as well as single-cell RNA sequencing, and its responsiveness to anti-TNF treatment was highlighted. By inhibiting the expression of KLK7, we further illustrated that keratinocytes have decreased proinflammatory responses to TNF. CONCLUSIONS: Our study implicates the genetic regulation of cytokine responses in predicting clinical drug response and supports the association between pharmacogenetic loci and anti-TNF response, as shown here for KLK7.
引用
- Zhang H, Patrick MT, Tejasvi T, et al. Retrospective pharmacogenetic study of psoriasis highlights the role of KLK7 in tumour necrosis factor signalling. Br J Dermatol. 2023. PMID: 37672660. doi:10.1093/bjd/ljad332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。